We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Moxonidine improves cardiac structure and performance in SHR through inhibition of cytokines, p38 MAPK and Akt.
- Authors
Aceros, H; Farah, G; Cobos-Puc, L; Stabile, A M; Noiseux, N; Mukaddam-Daher, S
- Abstract
Regression of left ventricular hypertrophy by moxonidine, a centrally acting sympatholytic imidazoline compound, results from a sustained reduction of DNA synthesis and transient stimulation of DNA fragmentation. Because apoptosis of cardiomyocytes may lead to contractile dysfunction, we investigated in spontaneously hypertensive rats (SHR), time- and dose-dependent effects of in vivo moxonidine treatment on cardiac structure and function as well as on the inflammatory process and signalling proteins involved in cardiac cell survival/death.
- Publication
British journal of pharmacology, 2011, Vol 164, Issue 3, p946
- ISSN
1476-5381
- Publication type
Journal Article
- DOI
10.1111/j.1476-5381.2011.01355.x